SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 24,381 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock in a transaction on Monday, July 20th. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49. Following the transaction, the chairman directly owned 3,512,822 shares in the company, valued at $22,095,650.38. This represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total value of $132,600.00.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $5.57 on Wednesday. The business has a fifty day simple moving average of $5.42 and a two-hundred day simple moving average of $5.09. SOPHiA GENETICS SA has a 1 year low of $2.92 and a 1 year high of $6.77. The company has a market capitalization of $467.27 million, a P/E ratio of -10.71 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. On average, analysts expect that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Analyst Ratings Changes

SOPH has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright initiated coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They set a “buy” rating and a $12.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. Akre Capital Management LLC increased its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at about $2,157,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $2,009,000. Finally, Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at about $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.